File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening

TitleDifferential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening
Authors
Issue Date2009
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
Citation
Gut, 2009, v. 58 n. 10, p. 1375-1381 How to Cite?
AbstractObjective: MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC). Methods: This study was divided into three phases: (1) marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of five patients with CRC, along with plasma from five healthy individuals as controls; (2) marker selection and validation by real-time quantitative RT-PCR on a small set of plasma; and (3) independent validation on a large set of plasma from 90 patients with CRC, 20 patients with gastric cancer, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. Results: Of the panel of 95 miRNAs analysed, five were upregulated both in plasma and tissue samples. All the five miRNAs were validated on the plasma of 25 patients with CRC and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in the patients with CRC (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 patients with CRC (p<0.05). Further validation with an independent set of plasma samples (n=180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cut-off of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. Conclusion: MiR-92 is significantly elevated in plasma of patients with CRC and can be a potential non-invasive molecular marker for CRC screening.
Persistent Identifierhttp://hdl.handle.net/10722/92202
ISSN
2015 Impact Factor: 14.921
2015 SCImago Journal Rankings: 6.474
ISI Accession Number ID
Funding AgencyGrant Number
CUHK Direct2041342
Institute of Digestive Disease
Li Ka Shing Institute of Health Science
Chinese University of Hong Kong
Funding Information:

The project was supported by the CUHK Direct Grant No. 2041342 and Research Funding from the Institute of Digestive Disease and the Li Ka Shing Institute of Health Science, the Chinese University of Hong Kong.

References

 

DC FieldValueLanguage
dc.contributor.authorNg, EKOen_HK
dc.contributor.authorChong, WWSen_HK
dc.contributor.authorJin, Hen_HK
dc.contributor.authorLam, EKYen_HK
dc.contributor.authorShin, VYen_HK
dc.contributor.authorYu, Jen_HK
dc.contributor.authorPoon, TCWen_HK
dc.contributor.authorNg, SSMen_HK
dc.contributor.authorSung, JJYen_HK
dc.date.accessioned2010-09-17T10:39:05Z-
dc.date.available2010-09-17T10:39:05Z-
dc.date.issued2009en_HK
dc.identifier.citationGut, 2009, v. 58 n. 10, p. 1375-1381en_HK
dc.identifier.issn0017-5749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92202-
dc.description.abstractObjective: MicroRNAs (miRNAs) have been shown to offer great potential in the diagnosis of cancer. We investigated whether plasma miRNAs could discriminate between patients with and without colorectal cancer (CRC). Methods: This study was divided into three phases: (1) marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of five patients with CRC, along with plasma from five healthy individuals as controls; (2) marker selection and validation by real-time quantitative RT-PCR on a small set of plasma; and (3) independent validation on a large set of plasma from 90 patients with CRC, 20 patients with gastric cancer, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls. Results: Of the panel of 95 miRNAs analysed, five were upregulated both in plasma and tissue samples. All the five miRNAs were validated on the plasma of 25 patients with CRC and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in the patients with CRC (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 patients with CRC (p<0.05). Further validation with an independent set of plasma samples (n=180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cut-off of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects. Conclusion: MiR-92 is significantly elevated in plasma of patients with CRC and can be a potential non-invasive molecular marker for CRC screening.en_HK
dc.languageengen_HK
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/en_HK
dc.relation.ispartofGuten_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshColorectal Neoplasms - diagnosis - genetics-
dc.subject.meshGene Expression Regulation, Neoplastic - genetics-
dc.subject.meshMicroRNAs - genetics - metabolism-
dc.subject.meshNeoplastic Cells, Circulating - metabolism-
dc.subject.meshTumor Markers, Biological - genetics - metabolism-
dc.titleDifferential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screeningen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0017-5749&volume=58&issue=10&spage=1375&epage=1381&date=2009&atitle=Differential+expression+of+microRNAs+in+plasma+of+patients+with+colorectal+cancer:+a+potential+marker+for+colorectal+cancer+screening-
dc.identifier.emailNg, EKO: ngko@hku.hken_HK
dc.identifier.authorityNg, EKO=rp01364en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1136/gut.2008.167817en_HK
dc.identifier.pmid19201770-
dc.identifier.scopuseid_2-s2.0-66049112674en_HK
dc.identifier.hkuros168708-
dc.identifier.hkuros194720-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-66049112674&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume58en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1375en_HK
dc.identifier.epage1381en_HK
dc.identifier.isiWOS:000269785500016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridNg, EKO=21135553700en_HK
dc.identifier.scopusauthoridChong, WWS=24576241300en_HK
dc.identifier.scopusauthoridJin, H=24577511700en_HK
dc.identifier.scopusauthoridLam, EKY=8644138600en_HK
dc.identifier.scopusauthoridShin, VY=7003491170en_HK
dc.identifier.scopusauthoridYu, J=35351306800en_HK
dc.identifier.scopusauthoridPoon, TCW=7006151710en_HK
dc.identifier.scopusauthoridNg, SSM=26021413400en_HK
dc.identifier.scopusauthoridSung, JJY=35405352400en_HK
dc.identifier.citeulike4434628-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats